Adial Pharmaceuticals, Inc. (ADIL )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ADIL
- Company Adial Pharmaceuticals, Inc.
- Price $3.98
- Changes Percentage -17.08
- Change -0.82
- Day Low $3.7
- Day High $4.87
- Year High $19
- Year Low $1.31
- Market Cap $2,802,160
- Price Avg 50 EMA (D) $2.52
- Price Avg 200 EMA (D) $4.29
- Exchange NASDAQ
- Volume 23,587
- Average Volume 466,391
- Open $4.8
- Previous Close $4.8
- EPS -5.47
- PE -0.53
- Earnings Announcement 2026-08-12 04:00:00
- Shares Outstanding $959,644
Company brief: ADIAL PHARMACEUTICALS, INC. (ADIL )
- Healthcare
- Biotechnology
- Mr. Cary John Claiborne MBA
- https://www.adialpharma.com
- US
- N/A
- 07-27-2018
- US00688A2050
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.